Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs a...( SAN DIEGO June 2 /- Amylin Pharma...)

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that the company will present new data for its FDA-approved diabetes drugs, BYETTA(R) (exenatide) injection and SYMLIN(R) (pramlintide acetate) injection, and its pipeline diabetes and obesity drug candidates at the American Diabetes Association's 68th Annual Scientific Sessions (ADA) being held in San Francisco, CA from June 6 to 10. The company will also host an investor presentation on Sunday, June 8, at 7:45 PM PT (10:45 PM ET) that will be available by webcast. ADA is one of the largest scientific meetings for endocrinologists and other health care professionals involved in diabetes research and the delivery of diabetes care.

Amylin will be introducing data through over 20 posters and eight oral presentations at the meeting. The data will demonstrate significant progress in key research and clinical programs that include studies of BYETTA, SYMLIN, and Amylin's early and late-stage pipeline candidates. Additional information will be presented during two symposia focused on the multi-hormonal approach to the treatment of diabetes and obesity, and the role of incretin-based therapies in type 2 diabetes.

"We are excited to demonstrate advancement in our diabetes and obesity pipeline programs at this year's ADA, particularly with updated data related to the once-weekly formulation of exenatide and the combination therapy program for obesity," said Daniel M. Bradbury, President and Chief Executive Officer, Amylin Pharmaceuticals, Inc. "At Amylin, we continually strive toward our mission of Challenging Science and Changing Lives. By challenging science we question conventional thinking, and open the door for truly innovative
'/>"/>